Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease
Primary Purpose
Type II Refractory Celiac Disease (RCD-II), In-situ Small Bowel T-cell Lymphoma
Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
AMG 714
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Type II Refractory Celiac Disease (RCD-II)
Eligibility Criteria
Inclusion Criteria:
- Confirmed diagnosis of refractory celiac disease Type II (RCD-II)
- Greater than 20% aberrant intraepithelial lymphocytes (IEL) as assessed by flow cytometry
- On a gluten-free diet for at least 6 months
- Avoid pregnancy
Exclusion Criteria:
- Enteropathy-Associated T cell Lymphoma (EATL)
- Infections
- Immune suppression
- Clinically significant co-morbidities
Sites / Locations
- Clinical Site
- Clinical Site
- Clinical Site
- Clinical Site
- Clinical Site
- Clinical Site
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
AMG 714
Placebo
Arm Description
Participants were administered 8 mg/kg AMG 714 via intravenous infusion on day 0, day 7 and every 2 weeks thereafter through week 10.
Participants were administered placebo via intravenous infusion on day 0, day 7 and every 2 weeks thereafter through week 10.
Outcomes
Primary Outcome Measures
Percent Change From Baseline in the Percentage of Aberrant Intestinal Intraepithelial Lymphocytes With Respect to All Intraepithelial Lymphocytes
The primary endpoint in this study was the change form baseline in the percentage of aberrant intestinal intraepithelial lymphocytes (IELs) with respect to total IELs, as assessed by flow cytometry (Immunological Response 1).
Intraepithelial lymphocytes (IELS) are white blood cells interspersed between epithelial cells of the small and large intestine where they function to preserve the integrity of the mucosal barrier by protecting the epithelium against pathogen or immune-induced pathology. In refractory coeliac disease type 2, aberrant intraepithelial lymphocytes make up 20% or more of total intraepithelial lymphocytes. Aberrant IELs were defined by flow cytometry as surface cluster of differentiation (CD)3-negative, intracellular CD3-positive IELs (sCD3-, icCD3+).
Secondary Outcome Measures
Percent Change From Baseline in the Percentage of Aberrant Intestinal Intraepithelial Lymphocytes With Respect to All Intestinal Epithelial Cells
Percent change from baseline in the percentage of aberrant intestinal IELs with respect to intestinal epithelial cells (Immunological Response 2) is a composite endpoint calculated by multiplying the percent of aberrant IEL versus total IELs (per flow cytometry) by the percent of total IEL versus intestinal epithelial cells as assessed by immunohistochemistry.
Percent Change From Baseline in Villous Height to Crypt Depth (VH:CD) Ratio
Villi are the small fingerlike projections that line the small intestine and promote nutrient absorption and are often shortened in patients with celiac disease. Crypts are grooves between the villi that are often elongated in patients with celiac disease. A decreased VH:CD ratio indicates worsening disease and increases in the VH:CD ratio indicate an improvement in the histology of intestinal mucosa (Histological Response).
Small bowel biopsies were performed at baseline and week 12; histological assessments were performed by a blinded central pathologist.
Percentage of Participants With Improvement in Marsh Score at Week 12
The Marsh classification system describes the stages of damage in the small intestine as seen under a microscope, with possible values of 0, 1, 2, 3a, 3b, or 3c. A score of 0 (best score) indicates that the intestinal lining is normal and celiac disease highly unlikely, a score of 3c (worst score) indicates increased intraepithelial lymphocytes, increased crypt hyperplasia and complete villi atrophy.
Improvement is defined as a lower grade on the Marsh score scale compared to baseline.
Percent Change From Baseline in Total Intraepithelial Lymphocyte Count at Week 12
Small bowel biopsies were performed at baseline and week 12; histological assessments were performed by a blinded central pathologist. The total IEL count is the density of IELs vs intestinal epithelial cells measured by immunohistochemistry.
Number of Weekly Bowel Movements at Baseline and Week 12
Participants were asked to record every bowel movement during the study using an electronic diary. If no bowel movements were experienced by the participant on any given day, the participant was required to document this in the diary.
Percentage of Participants With Diarrhea at Baseline and Week 12
The Bristol Stool Form Scale (BSFS) is a pictorial aid to help participants identify the shape and consistency of their bowel movements. Participants were asked to complete this form daily using an electronic diary at the time of each bowel movement. The BSFS categorizes bowel movements into 7 types, from Type 1 (separate hard lumps, like nuts; hard to pass) to Type 7 (watery, no solid pieces, entirely liquid).
Diarrhoea was defined at least one BSFS score >= 6 for the given week.
Change From Baseline in Total Weekly Gastrointestinal Symptom Rating Scale (GSRS) Score at Week 12
The GSRS is a 15-question 7-scale questionnaire used to assess 5 dimensions of gastrointestinal syndromes: diarrhea, indigestion, constipation, abdominal pain and reflux. Questions are scored between 1 (no discomfort at all) and 7 (very severe discomfort).
The total GSRS score is calculated as the sum of the scores of all 15 questions, and ranges from 15 (no discomfort at all) to 105 (very severe discomfort in all 5 dimensions of gastrointestinal syndromes).
Change From Baseline in Total Celiac Disease GSRS (CeD-GSRS) Score at Week 12
The CeD-GSRS score is derived from a subset of 10 questions from the GSRS questionnaire (questions 1, 4-9, 11, 12 and 14), which are each assessed on a scale of 1 (no discomfort at all) to 7 (very severe discomfort).
The total CeD-GSRS score ranges from 10 (no discomfort at all) to 70 (very severe discomfort in all celiac syndromes).
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02633020
Brief Title
Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease
Official Title
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease, an In Situ Small Bowel T Cell Lymphoma
Study Type
Interventional
2. Study Status
Record Verification Date
November 2019
Overall Recruitment Status
Completed
Study Start Date
April 13, 2016 (Actual)
Primary Completion Date
April 11, 2017 (Actual)
Study Completion Date
May 2, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Amgen
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Protocol CELIM-RCD-002 is designed to evaluate the efficacy and safety of AMG 714 for the treatment of adult patients with type II refractory celiac disease (RCD-II), an in-situ small bowel T-cell lymphoma.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type II Refractory Celiac Disease (RCD-II), In-situ Small Bowel T-cell Lymphoma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
28 (Actual)
8. Arms, Groups, and Interventions
Arm Title
AMG 714
Arm Type
Experimental
Arm Description
Participants were administered 8 mg/kg AMG 714 via intravenous infusion on day 0, day 7 and every 2 weeks thereafter through week 10.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants were administered placebo via intravenous infusion on day 0, day 7 and every 2 weeks thereafter through week 10.
Intervention Type
Biological
Intervention Name(s)
AMG 714
Intervention Description
Administered via a 120-minute IV infusion for a total of 7 times over 10 weeks.
Intervention Type
Biological
Intervention Name(s)
Placebo
Intervention Description
Administered via a 120-minute IV infusion for a total of 7 times over 10 weeks.
Primary Outcome Measure Information:
Title
Percent Change From Baseline in the Percentage of Aberrant Intestinal Intraepithelial Lymphocytes With Respect to All Intraepithelial Lymphocytes
Description
The primary endpoint in this study was the change form baseline in the percentage of aberrant intestinal intraepithelial lymphocytes (IELs) with respect to total IELs, as assessed by flow cytometry (Immunological Response 1).
Intraepithelial lymphocytes (IELS) are white blood cells interspersed between epithelial cells of the small and large intestine where they function to preserve the integrity of the mucosal barrier by protecting the epithelium against pathogen or immune-induced pathology. In refractory coeliac disease type 2, aberrant intraepithelial lymphocytes make up 20% or more of total intraepithelial lymphocytes. Aberrant IELs were defined by flow cytometry as surface cluster of differentiation (CD)3-negative, intracellular CD3-positive IELs (sCD3-, icCD3+).
Time Frame
Baseline and week 12
Secondary Outcome Measure Information:
Title
Percent Change From Baseline in the Percentage of Aberrant Intestinal Intraepithelial Lymphocytes With Respect to All Intestinal Epithelial Cells
Description
Percent change from baseline in the percentage of aberrant intestinal IELs with respect to intestinal epithelial cells (Immunological Response 2) is a composite endpoint calculated by multiplying the percent of aberrant IEL versus total IELs (per flow cytometry) by the percent of total IEL versus intestinal epithelial cells as assessed by immunohistochemistry.
Time Frame
Baseline and week 12
Title
Percent Change From Baseline in Villous Height to Crypt Depth (VH:CD) Ratio
Description
Villi are the small fingerlike projections that line the small intestine and promote nutrient absorption and are often shortened in patients with celiac disease. Crypts are grooves between the villi that are often elongated in patients with celiac disease. A decreased VH:CD ratio indicates worsening disease and increases in the VH:CD ratio indicate an improvement in the histology of intestinal mucosa (Histological Response).
Small bowel biopsies were performed at baseline and week 12; histological assessments were performed by a blinded central pathologist.
Time Frame
Baseline and week 12
Title
Percentage of Participants With Improvement in Marsh Score at Week 12
Description
The Marsh classification system describes the stages of damage in the small intestine as seen under a microscope, with possible values of 0, 1, 2, 3a, 3b, or 3c. A score of 0 (best score) indicates that the intestinal lining is normal and celiac disease highly unlikely, a score of 3c (worst score) indicates increased intraepithelial lymphocytes, increased crypt hyperplasia and complete villi atrophy.
Improvement is defined as a lower grade on the Marsh score scale compared to baseline.
Time Frame
Baseline and week 12
Title
Percent Change From Baseline in Total Intraepithelial Lymphocyte Count at Week 12
Description
Small bowel biopsies were performed at baseline and week 12; histological assessments were performed by a blinded central pathologist. The total IEL count is the density of IELs vs intestinal epithelial cells measured by immunohistochemistry.
Time Frame
Baseline and week 12
Title
Number of Weekly Bowel Movements at Baseline and Week 12
Description
Participants were asked to record every bowel movement during the study using an electronic diary. If no bowel movements were experienced by the participant on any given day, the participant was required to document this in the diary.
Time Frame
Baseline and week 12
Title
Percentage of Participants With Diarrhea at Baseline and Week 12
Description
The Bristol Stool Form Scale (BSFS) is a pictorial aid to help participants identify the shape and consistency of their bowel movements. Participants were asked to complete this form daily using an electronic diary at the time of each bowel movement. The BSFS categorizes bowel movements into 7 types, from Type 1 (separate hard lumps, like nuts; hard to pass) to Type 7 (watery, no solid pieces, entirely liquid).
Diarrhoea was defined at least one BSFS score >= 6 for the given week.
Time Frame
Baseline and week 12
Title
Change From Baseline in Total Weekly Gastrointestinal Symptom Rating Scale (GSRS) Score at Week 12
Description
The GSRS is a 15-question 7-scale questionnaire used to assess 5 dimensions of gastrointestinal syndromes: diarrhea, indigestion, constipation, abdominal pain and reflux. Questions are scored between 1 (no discomfort at all) and 7 (very severe discomfort).
The total GSRS score is calculated as the sum of the scores of all 15 questions, and ranges from 15 (no discomfort at all) to 105 (very severe discomfort in all 5 dimensions of gastrointestinal syndromes).
Time Frame
Baseline and week 12
Title
Change From Baseline in Total Celiac Disease GSRS (CeD-GSRS) Score at Week 12
Description
The CeD-GSRS score is derived from a subset of 10 questions from the GSRS questionnaire (questions 1, 4-9, 11, 12 and 14), which are each assessed on a scale of 1 (no discomfort at all) to 7 (very severe discomfort).
The total CeD-GSRS score ranges from 10 (no discomfort at all) to 70 (very severe discomfort in all celiac syndromes).
Time Frame
Baseline and week 12
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Confirmed diagnosis of refractory celiac disease Type II (RCD-II)
Greater than 20% aberrant intraepithelial lymphocytes (IEL) as assessed by flow cytometry
On a gluten-free diet for at least 6 months
Avoid pregnancy
Exclusion Criteria:
Enteropathy-Associated T cell Lymphoma (EATL)
Infections
Immune suppression
Clinically significant co-morbidities
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Amgen, MD
Organizational Affiliation
Amgen
Official's Role
Study Director
Facility Information:
Facility Name
Clinical Site
City
San Diego
State/Province
California
Country
United States
Facility Name
Clinical Site
City
New York
State/Province
New York
Country
United States
Facility Name
Clinical Site
City
Tampere
Country
Finland
Facility Name
Clinical Site
City
Paris
Country
France
Facility Name
Clinical Site
City
Amsterdam
Country
Netherlands
Facility Name
Clinical Site
City
Madrid
Country
Spain
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Publication in peer-reviewed journals
Citations:
PubMed Identifier
31494097
Citation
Cellier C, Bouma G, van Gils T, Khater S, Malamut G, Crespo L, Collin P, Green PHR, Crowe SE, Tsuji W, Butz E, Cerf-Bensussan N, Macintyre E, Parnes JR, Leon F, Hermine O, Mulder CJ; RCD-II Study Group Investigators. Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study. Lancet Gastroenterol Hepatol. 2019 Dec;4(12):960-970. doi: 10.1016/S2468-1253(19)30265-1. Epub 2019 Sep 4.
Results Reference
derived
Links:
URL
http://www.celimmune.com
Description
Related Info
Learn more about this trial
Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease
We'll reach out to this number within 24 hrs